Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)

被引：0
|
作者：
Strik, A. [1 ]
van de Vrie, W. [2 ]
Bloemsaat-Minekus, J. [3 ]
Nurmohamed, M. [4 ]
Bossuyt, P. [5 ]
Bodelier, A. [6 ]
Rispens, T. [7 ]
van Megen, Y. [3 ]
D'Haens, G. [1 ]
机构：
[1] Acad Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Albert Schweitzer Hosp, Dept Gastroenterol & Hepatol, Dordrecht, Netherlands
[3] Mundipharma Pharmaceut BV, Hoevelaken, Netherlands
[4] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[5] Imelda Hosp, Bonheiden, Belgium
[6] Amphia Hosp Breda Loc Langendijk, Breda, Netherlands
[7] Tytgat Inst Intestinal & Liver Res, AMC, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P724
引用
收藏
页码：S477 / S478
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
    Jung, Yoon Suk
    Park, Dong Il
    Kim, Young Ho
    Lee, Ji Hyun
    Seo, Pyoung Ju
    Cheon, Jae Hee
    Kang, Hyoun Woo
    Kim, Ji Won
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (12) : 1705 - 1712
  • [42] Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases
    Sieczkowska, Joanna
    Jarzebicka, Dorota
    Meglicka, Monika
    Oracz, Grzegorz
    Kierkus, Jaroslaw
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (05) : 729 - 735
  • [43] Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
    Goll, Guro Lovik
    Olsen, Inge C.
    Jorgensen, Kristin K.
    Lorentzen, Merete
    Bolstad, Nils
    Haavardsholm, Espen A.
    Lundin, Knut E. A.
    Mork, Cato
    Jahnsen, Jorgen
    Kvien, Tore K.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [44] Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 and Then to GP1111
    Nabi, Hafsah
    Glintborg, Bente
    Loft, Anne Gitte
    Hendricks, Oliver
    Pedersen, Jens Kristian
    Just, Soren Andreas
    Ahmed, Rabiah
    Danebod, Kamilla
    Munk, Heidi
    Colic, Ada
    Linauskas, Asta
    Jensen, Dorte Vendelbo
    Raun, Johnny
    Grydehoj, Jolanta
    Christensen, Louise Brot
    Manilo, Natalia
    Lomborg, Niels
    Kristensen, Salome
    Mehnert, Frank
    Krogh, Niels Steen
    Hetland, Merete
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1161 - 1163
  • [45] Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful
    Gervais, Lisa
    McLean, Luke L.
    Wilson, Michelle L.
    Cameron, Carol
    Curtis, Lee
    Garrick, Vikki
    Armstrong, Kat
    Tayler, Rachel
    Henderson, Paul
    Hansen, Richard
    Chalmers, Iain
    Wilson, David C.
    Russell, Richard K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (06): : 745 - 748
  • [46] EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS
    Privitera, G.
    Pugliese, D.
    Tolusso, B.
    Gremese, E.
    Papa, A.
    Papparella, L. G.
    Gasbarrini, A.
    Rapaccini, G. L.
    Guidi, L.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S10 - S11
  • [47] EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS
    Privitera, Giuseppe
    Pugliese, Daniela
    Tolusso, Barbara
    Gremese, Elisa
    Papa, Alfredo
    Papparella, Luigi Giovanni
    Gasbarrini, Antonio
    Rapaccini, Gian Lodovico
    Guidi, Luisa
    Armuzzi, Alessandro
    GASTROENTEROLOGY, 2020, 158 (06) : S462 - S462
  • [48] SWITCHING FROM ORIGINATOR INFLIXIMAB TO CT-P13: A UK SINGLE CENTRE EXPERIENCE
    Bhandare, Anirudh Pramod
    Crooks, Benjamin
    Nigam, Gaurav Bhaskar
    Limdi, Jimmy K.
    GUT, 2019, 68 : A70 - A70
  • [49] Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
    Yoo, Dae Hyun
    Prodanovic, Nenad
    Jaworski, Janusz
    Miranda, Pedro
    Ramiterre, Edgar
    Lanzon, Allan
    Baranauskaite, Asta
    Wiland, Piotr
    Abud-Mendoza, Carlos
    Oparanov, Boycho
    Smiyan, Svitlana
    Kim, HoUng
    Lee, Sang Joon
    Kim, SuYeon
    Park, Won
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 355 - 363
  • [50] Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
    Smits, L.
    Derikx, L.
    Drenth, J.
    de Jong, D.
    van Esch, A.
    Hoentjen, F.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S44 - S45
12345